Ajanta Pharma Announces Launch of Omeprazole and Sodium Bicarbonate Powder for Oral Suspension

Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announces the launch of Omeprazole and Sodium Bicarbonate Powder for Oral Suspension, a bioequivalent prescription generic version of Zegerid® Powder for Oral Suspension (20mg/1680mg and 40mg/1680mg), into the US market.

Omeprazole and Sodium Bicarbonate Powder for Oral Suspension is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Applications (ANDAs) of which it has 14 final ANDA approvals; 2 tentative approvals; and 10 ANDAs under review with the United States Food & Drug Administration.